Literature DB >> 31992178

Novel Chronic Mouse Model of Cerebral Cavernous Malformations.

Cécile Cardoso1, Minh Arnould1, Coralie De Luca1, Cécile Otten2, Salim Abdelilah-Seyfried2,3, Alonso Heredia4, Anne-Louise Leutenegger1, Markus Schwaninger5, Elisabeth Tournier-Lasserve1,6, Gwénola Boulday1.   

Abstract

Background and Purpose- Cerebral cavernous malformations (CCMs) are vascular malformations of the brain that lead to cerebral hemorrhages. A pharmacological treatment is needed especially for patients with nonoperable deep-seated lesions. We and others obtained CCM mouse models that were useful for mechanistic studies and rapid trials testing the preventive effects of candidate drugs. The shortened lifespan of acute mouse models hampered evaluation of compounds that would not only prevent lesion appearance but also cure preexisting lesions. Indirubin-3'-monoxime previously demonstrated its efficacy to reverse the cardiac phenotype of ccm2m201 zebrafish mutants and to prevent lesion development in an acute CCM2 mouse model. In the present article, we developed and characterized a novel chronic CCM2 mouse model and evaluated the curative therapeutic effect of indirubin-3'-monoxime after CCM lesion development. Methods- The chronic mouse model was obtained by a postnatal induction of brain-endothelial-cell-specific ablation of the Ccm2 gene using the inducible Slco1c1-CreERT2 mouse line. Results- We obtained a fully penetrant novel CCM chronic mouse model without any obvious off-target phenotypes and compatible with long-term survival. By 3 months of age, CCM lesions ranging in size from small isolated lesions to multiple caverns developed throughout the brain. Lesion burden was quantified in animals from 1 week to 5 months of age. Clear signs of intracerebral hemorrhages were noticed in brain-endothelial-cell-specific ablation of the Ccm2 gene. In contrast with its preventive effect in the acute CCM2 mouse model, a 20 mg/kg indirubin-3'-monoxime treatment for 3 weeks in 3-month old animals neither had any beneficial effect on the lesion burden nor alleviated cerebral hemorrhages. Conclusions- The brain-endothelial-cell-specific ablation of the Ccm2 gene chronic model is a strongly improved disease model for the CCM community whose challenge today is to decipher which candidate drugs might have a curative effect on patients' preexisting lesions. Visual Overview- An online visual overview is available for this article.

Entities:  

Keywords:  cavernous; central nervous system; cerebral hemorrhage; cerebrovascular disorders; hemangioma; models, animal; therapeutics

Year:  2020        PMID: 31992178     DOI: 10.1161/STROKEAHA.119.027207

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

Review 1.  Cerebral Cavernous Malformation Pathogenesis: Investigating Lesion Formation and Progression with Animal Models.

Authors:  Chelsea M Phillips; Svetlana M Stamatovic; Richard F Keep; Anuska V Andjelkovic
Journal:  Int J Mol Sci       Date:  2022-04-30       Impact factor: 6.208

2.  Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations.

Authors:  Wenqing Li; Virginia Tran; Iftach Shaked; Belinda Xue; Thomas Moore; Rhonda Lightle; David Kleinfeld; Issam A Awad; Mark H Ginsberg
Journal:  Elife       Date:  2021-05-20       Impact factor: 8.140

Review 3.  Mouse models of vascular development and disease.

Authors:  Ondine Cleaver
Journal:  Curr Opin Hematol       Date:  2021-05-01       Impact factor: 3.218

4.  Caveolae-mediated Tie2 signaling contributes to CCM pathogenesis in a brain endothelial cell-specific Pdcd10-deficient mouse model.

Authors:  Lingfeng Qin; Quan Jiang; Katie N Murray; Haifeng Zhang; Huanjiao Jenny Zhou; Busu Li; Qun Lin; Morven Graham; Xinran Liu; Jaime Grutzendler; Wang Min
Journal:  Nat Commun       Date:  2021-01-25       Impact factor: 14.919

5.  A murine model of cerebral cavernous malformations with acute hemorrhage.

Authors:  Claudio Maderna; Federica Pisati; Claudio Tripodo; Elisabetta Dejana; Matteo Malinverno
Journal:  iScience       Date:  2022-02-18

6.  Novel Murine Models of Cerebral Cavernous Malformations.

Authors:  Matthew R Detter; Robert Shenkar; Christian R Benavides; Catherine A Neilson; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Le Shen; Ying Cao; Romuald Girard; Dongdong Zhang; Erin Griffin; Carol J Gallione; Issam A Awad; Douglas A Marchuk
Journal:  Angiogenesis       Date:  2020-07-24       Impact factor: 9.596

7.  Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.

Authors:  Miguel Alejandro Lopez-Ramirez; Catherine Chinhchu Lai; Shady Ibrahim Soliman; Preston Hale; Angela Pham; Esau J Estrada; Sara McCurdy; Romuald Girard; Riya Verma; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Robert Shenkar; Orit Poulsen; Gabriel G Haddad; Richard Daneman; Brendan Gongol; Hao Sun; Frederic Lagarrigue; Issam A Awad; Mark H Ginsberg
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.